Breo Ellipta Sales Below Estimates, Says Leerink Swann (THRX) (GSK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
Theravance (THRX) Anoro COPD Studies Gives Baird Increased Confidence
March 14, 2014 10:32 AM EDTBaird analyst Brian Skorney has increased confidence in the potential of Theravance Inc. (NASDAQ: THRX) Anoro following randomized COPD studies. He reiterated an Outperform rating and price target of $44.00.
Skorney commented, "With positive results across three studies against either dose of fluticasone... More
